Protein Biomarkers of New-Onset Heart Failure: Insights From the Heart Omics and Ageing Cohort, the Atherosclerosis Risk in Communities Study, and the Framingham Heart Study
Authors:
- Nicolas GirerdNGNicolas Girerd
- Daniel LevyDLDaniel Levy
- Kevin DuarteKDKevin Duarte
- Joao Pedro FerreiraJFJoao Pedro Ferreira
- Christie BallantyneCBChristie Ballantyne
- Timothy CollierTCTimothy Collier
- Anne PizardAPAnne Pizard
- Jens BjörkmanJBJens Björkman
- Javed ButlerJBJaved Butler
- Andrew ClarkACAndrew Clark
- John G. ClelandJCJohn G. Cleland
- Christian DellesCDChristian Delles
Open Access
- 1 May 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 16 (5) , 426-441
Abstract
Background: We sought to identify protein biomarkers of new-onset heart failure (HF) in 3 independent cohorts (HOMAGE cohort [Heart Omics and Ageing], ARIC study [Atherosclerosis Risk in Communities], and FHS [Framingham Heart Study]) and assess if and to what extent they improve HF risk prediction compared to clinical risk factors alone. Methods: A nested case-control design was used with cases (incident HF) and controls (without HF) matched on age and sex within each cohort. Plasma concentrations of 276 proteins were measured at baseline in ARIC (250 cases/250 controls), FHS (191/191), and HOMAGE cohort (562/871). Results: In single protein analysis, after adjusting for matching variables and clinical risk factors (and correcting for multiple testing), 62 proteins were associated with incident HF in ARIC, 16 in FHS, and 116 in HOMAGE cohort. Proteins associated with incident HF in all cohorts were BNP (brain natriuretic peptide), NT-proBNP (N-terminal pro-B-type natriuretic peptide), eukaryotic translation initiation factor 4E-BP1 (4E-binding protein 1), hepatocyte growth factor (HGF), Gal-9 (galectin-9), TGF-alpha (transforming growth factor alpha), THBS2 (thrombospondin-2), and U-PAR (urokinase plasminogen activator surface receptor). The increment in C -index for incident HF based on a multiprotein biomarker approach, in addition to clinical risk factors and NT-proBNP, was 11.1% (7.5%–14.7%) in ARIC, 5.9% (2.6%–9.2%) in FHS, and 7.5% (5.4%–9.5%) in HOMAGE cohort, all P <0.001), each of which was a larger increase than that for NT-proBNP on top of clinical risk factors. Complex network analysis revealed a number of overrepresented pathways related to inflammation (eg, tumor necrosis factor and interleukin) and remodeling (eg, extracellular matrix and apoptosis). Conclusions: A multiprotein biomarker approach improves prediction of incident HF when added to natriuretic peptides and clinical risk factors.Keywords
This publication has 32 references indexed in Scilit:
- Prognostic Utility of Novel Biomarkers of Cardiovascular StressCirculation, 2012
- clusterMaker: a multi-algorithm clustering plugin for CytoscapeBMC Bioinformatics, 2011
- Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human bloodNucleic Acids Research, 2011
- GLay: community structure analysis of biological networksBioinformatics, 2010
- On the Operational Characteristics of the Benjamini and Hochberg False Discovery Rate ProcedureStatistical Applications in Genetics and Molecular Biology, 2007
- Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction NetworksGenome Research, 2003
- The nested case-control study in cardiologyAmerican Heart Journal, 2003
- Changes in notions about heart failureThe Lancet, 2001
- Epidemiology, aetiology, and prognosis of heart failureHeart, 2000
- The design of a prospective study of pravastatin in the elderly at risk (PROSPER)The American Journal of Cardiology, 1999